EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia

Jaimal Kothari iD, Toby Eyre iD, Ali Rismani, Kushani Ediriwickrema iD, Darren Edwards, Sevasti Galani, William Wilson, Anthony Lawrie, Laura Clifton-Hadley, Helen McCarthy, Angela Collins, David Lewis und 6 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19706 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Jaimal Kothari und 17 weiteren Autor:innen. Beteiligte Einrichtung: Oxford University Hospitals NHS Trust, Oxford, United Kingdom of Great Britain and Northern Ireland. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Rituximab, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp and Dohme United Kingdom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The optimal therapeutic approach for relapsed/refractory (R/R) Waldenström's Macroglobulinaemia (WM) has not been clearly defined, especially after treatment with chemoimmunotherapy (CIT) and covalent Bruton's tyrosine kinase inhibitors (cBTKi). The PembroWM trial is a multi‐centre, phase II, single‐arm study assessing the safety, tolerability and efficacy of rituximab with pembrolizumab in R/R WM patients who had received at least one prior line of treatment, with all having relapsed post‐CIT and most also exposed to cBTKi. A total of 17 patients were enrolled, with a median age of 70, and median of three prior lines of therapy with 15 either refractory or intolerant of a cBTKi. A significant proportion was identified as genomically high risk with BTKC481, CXCR4 and MYD88 L265P wild‐type aberrations. Twenty‐four‐week overall response rate was 50% (60% CI 39.3%–60.7%), and median duration of response was 11.6 months (IQR: 6.3–17). The median progression‐free survival was 13.6 months (95% CI 3–19.8), and the median overall survival (OS) was not reached. Treatment was well tolerated, with minimal numbers of immune‐mediated AEs typically seen with checkpoint inhibitors. PembroWM is the first study to evaluate the feasibility of PD‐1 axis modulation in WM and has shown that in combination with Rituximab the combination is safe and deliverable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaRituximabAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansAgedFemaleMaleMiddle AgedAged, 80 and overRecurrence

Stichwörter der Autor:innen

Waldenstrom's Macroglobulinaemiaclinical trialshaematological malignancymalignant haematologytherapytrials

Substanzen

RituximabpembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom of Great Britain and Northern Ireland.
  • University College Hospital, London, United Kingdom of Great Britain and Northern Ireland.
  • Cancer Research UK and University College London Cancer Trials Centre, London, United Kingdom of Great Britain and Northern Ireland.
  • University Hospitals Dorset NHS Foundation Trust, Bournemouth, United Kingdom of Great Britain and Northern Ireland.
  • Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom of Great Britain and Northern Ireland.
  • Derriford Hospital, Plymouth, United Kingdom of Great Britain and Northern Ireland.

ORCID-Profile: Jaimal Kothari, Toby Eyre, Kushani Ediriwickrema, Guy Pratt, Ruth de Tute

Förderung

  • Merck Sharp and Dohme United Kingdom

Zitieren

APA

Kothari, J., Eyre, T., Rismani, A., Ediriwickrema, K., Edwards, D., Galani, S., Wilson, W., Lawrie, A., Clifton-Hadley, L., McCarthy, H., Collins, A., Lewis, D., Arulogan, S., Auer, R., Pratt, G., de Tute, R., Owen, R., & D'Sa, S. (2024). PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.19706

Vancouver

Kothari J, Eyre T, Rismani A, Ediriwickrema K, Edwards D, Galani S, et al. PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia. British Journal of Haematology. 2024. doi:10.1111/bjh.19706

BibTeX
@article{Kothari2024,
  author = {Kothari, Jaimal and Eyre, Toby and Rismani, Ali and Ediriwickrema, Kushani and Edwards, Darren and Galani, Sevasti and Wilson, William and Lawrie, Anthony and Clifton-Hadley, Laura and McCarthy, Helen and Collins, Angela and Lewis, David and Arulogan, Suzanne and Auer, Rebecca and Pratt, Guy and de Tute, Ruth and Owen, Roger and D'Sa, Shirley},
  title = {PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19706}
}
Kostenlos starten →